Business
Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025
BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will host a virtual key opinion leader (KOL) event on Monday, October 20, 2025 at 8:00 AM ET featuring company leadership and Kyriakos Papadopoulos, MD (Co-Director of Clinical Research at START, San Antonio), who will discuss the unmet need and current t
About this update from Sensei Biotherapeutics, Inc.
[{"type":"image","alt":"Sensei Biotherapeutics","displaySize":"","headline":null,"caption":"Sensei Biotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":111,"url":"https://media.zenfs.com/en/globenewswire.com/0bb46371fbe8afb08b27525aefb81405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tSVB9mWPe6cbY7LRif6RFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0bb46371fbe8afb08b27525aefb81405","width":300,"height":111}},"lazy":false},{"type":"text","content":"BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will host a virtual key opinion leader (KOL) event on Monday, October 20, 2025 at 8:00 AM ET featuring company leadership and Kyriakos Papadopoulos, MD (Co-Director of Clinical Research at START, San Antonio), who will discuss the unmet need and current treatment landscape for immunotherapy-resistant solid tumors. To register, click here.","length":585,"tagName":"p"},{"type":"text","content":"The event will provide an update on the Company's plans for Phase 2 studies and data from the full Phase 1/2 dose expansion cohort, including from the ESMO oral presentation on Friday, October 17th. Solnerstotug (formerly SNS-101), is a conditionally active monoclonal antibody targeting VISTA (V-domain Ig suppressor of T cell activation) in PD-(L)1 resistant tumors.","length":372,"tagName":"p"},{"type":"text","content":"A live question and answer session will follow the formal presentations.","length":72,"tagName":"p"},{"type":"text","content":"About Kyriakos Papadopoulos, MDKyriakos Papadopoulos, MD is the Co-Director of Clinical Research at START in San Antonio, Texas. He is board-certified in Internal Medicine, Medical Oncology & Hematology. His clinical interests include drug development and malignancies of the upper gastrointestinal-tract and lungs. Dr. Papadopoulos completed his MBBCh and MSc (Med) at the University of Witwatersrand, Johannesburg, and his specialty training in Internal Medicine at Groote Schuur Hospital, Cape Town, South Africa. He followed this with a fellowship in Medical Oncology and Hematology at the College of Physicians and Surgeons of Co...